Shucheng Liang
Research Subjects
Shucheng Liang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Wengen Zhu
Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China
2 shared publications Chaokun Guan
Department of Cardiology, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, Hubei, China
1 shared publication- Danghan Wang
Macau University of Science and Technology
1 shared publication Guigao Guo
Department of Cardiovascular, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
1 shared publication- Hao Liu
Guangxi Medical University
1 shared publication Kai Qiu
Sanming First Affiliated Hospital of Fujian Medical University
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Oral Anticoagulation Monotherapy vs Dual-Pathway Antithrombotic Therapy in Chronic Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: This study aimed to systematically review randomized controlled trials (RCTs) comparing oral anticoagulant (OAC) monotherapy with combination therapy of OAC plus single antiplatelet therapy (SAPT) in patients with chronic coronary syndrome (CCS) and an indication for long-term anticoagulation. Methods: A systematic screening of the PubMed, EMBASE and Cochrane Central databases was conducted until 12 Mar 2026 to identify RCTs comparing OAC monotherapy with OAC plus SAPT in CCS patients. The primary endpoints were all-cause mortality and net adverse clinical events (NACE). Secondary endpoints included major bleeding, cardiovascular death, myocardial infarction, ischemic stroke and stroke. End point data were pooled using random-effect models, to generate hazard ratios (HR) and odds ratios (OR) and corresponding 95% confidence intervals (CI). Results: Six RCTs involving 5048 patients were included. Pooled analysis showed that OAC monotherapy significantly reduced the risk of NACE compared to combination therapy (HR, 0.66; 95% CI, 0.44–0.77). There was no significant difference in all-cause mortality overall (HR, 0.75; 95% CI, 0.51–1.10). OAC monotherapy substantially decreased major bleeding (HR, 0.47; 95% CI, 0.32–0.70) and cardiovascular death (HR, 0.69; 95% CI 0.50–0.95) and there was no statistically significant difference in other secondary outcomes. Conclusions: Current evidence suggests that OAC monotherapy is a safer alternative to combination therapy in anticoagulated patients with CCS, without increasing ischemic risk.
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessOral Anticoagulation Monotherapy vs Dual-Pathway Antithrombotic Therapy in Chronic Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: This study aimed to systematically review randomized controlled trials (RCTs) comparing oral anticoagulant (OAC) monotherapy with combination therapy of OAC plus single antiplatelet therapy (SAPT) in patients with chronic coronary syndrome (CCS) and an indication for long-term anticoagulation. Methods: A systematic screening of the PubMed, EMBASE and Cochrane Central databases was conducted until 12 Mar 2026 to identify RCTs comparing OAC monotherapy with OAC plus SAPT in CCS patients. The primary endpoints were all-cause mortality and net adverse clinical events (NACE). Secondary endpoints included major bleeding, cardiovascular death, myocardial infarction, ischemic stroke and stroke. End point data were pooled using random-effect models, to generate hazard ratios (HR) and odds ratios (OR) and corresponding 95% confidence intervals (CI). Results: Six RCTs involving 5048 patients were included. Pooled analysis showed that OAC monotherapy significantly reduced the risk of NACE compared to combination therapy (HR, 0.66; 95% CI, 0.44–0.77). There was no significant difference in all-cause mortality overall (HR, 0.75; 95% CI, 0.51–1.10). OAC monotherapy substantially decreased major bleeding (HR, 0.47; 95% CI, 0.32–0.70) and cardiovascular death (HR, 0.69; 95% CI 0.50–0.95) and there was no statistically significant difference in other secondary outcomes. Conclusions: Current evidence suggests that OAC monotherapy is a safer alternative to combination therapy in anticoagulated patients with CCS, without increasing ischemic risk.
- Open Access
- 13 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26948
Direct Oral Anticoagulants vs. Vitamin K Antagonists for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-analysis
Background: This study aimed to systematically review and synthesize evidence comparing direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) for anticoagulation in patients with atrial fibrillation (AF) and cardiac amyloidosis (CA). Methods: A comprehensive search of PubMed and EMBASE databases was conducted through January 2024 to identify studies comparing DOACs and VKAs in AF patients with CA. Eligible studies underwent rigorous screening and data extraction to evaluate safety and efficacy outcomes. Results: Four studies met the criteria. The first study reported similar embolic event rates between DOACs (3.9%) and VKAs (2.9%) per 100 patient years, while major bleeding rates were 5.21% and 3.74%, respectively. The second paper found stroke rates of 2% for DOACs and 4% for VKAs, with bleeding complications observed in 10% of DOAC patients compared to 20% in VKA patients. The third cohort demonstrated that DOACs were associated with significantly lower risks of stroke and major bleeding compared to VKAs. The last study reported embolic event rates of 1.6 and 2.0 per 100 patient years for DOACs and VKAs, respectively. In the pooled analysis, DOACs were associated with a reduced risk of thromboembolic events (odds ratio [OR] = 0.52; 95% confidence interval [CI]: 0.32–0.84), and no difference in major bleeding between the two groups (OR = 0.61, 95% CI: 0.25–1.51). Conclusions: Existing studies support the use of DOACs as a non-inferior therapeutic option compared to VKAs for preventing thromboembolism in patients with AF and cardiac amyloidosis. DOACs may also offer practical advantages, including reduced bleeding risks and ease of management, but further high-quality randomized controlled trials are needed to confirm these findings and guide clinical practice.
- 13 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26948
Open AccessDirect Oral Anticoagulants vs. Vitamin K Antagonists for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-analysis
Background: This study aimed to systematically review and synthesize evidence comparing direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) for anticoagulation in patients with atrial fibrillation (AF) and cardiac amyloidosis (CA). Methods: A comprehensive search of PubMed and EMBASE databases was conducted through January 2024 to identify studies comparing DOACs and VKAs in AF patients with CA. Eligible studies underwent rigorous screening and data extraction to evaluate safety and efficacy outcomes. Results: Four studies met the criteria. The first study reported similar embolic event rates between DOACs (3.9%) and VKAs (2.9%) per 100 patient years, while major bleeding rates were 5.21% and 3.74%, respectively. The second paper found stroke rates of 2% for DOACs and 4% for VKAs, with bleeding complications observed in 10% of DOAC patients compared to 20% in VKA patients. The third cohort demonstrated that DOACs were associated with significantly lower risks of stroke and major bleeding compared to VKAs. The last study reported embolic event rates of 1.6 and 2.0 per 100 patient years for DOACs and VKAs, respectively. In the pooled analysis, DOACs were associated with a reduced risk of thromboembolic events (odds ratio [OR] = 0.52; 95% confidence interval [CI]: 0.32–0.84), and no difference in major bleeding between the two groups (OR = 0.61, 95% CI: 0.25–1.51). Conclusions: Existing studies support the use of DOACs as a non-inferior therapeutic option compared to VKAs for preventing thromboembolism in patients with AF and cardiac amyloidosis. DOACs may also offer practical advantages, including reduced bleeding risks and ease of management, but further high-quality randomized controlled trials are needed to confirm these findings and guide clinical practice.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Systematic Review of Randomized Clinical Trials on Direct Oral Anticoagulants in Pediatric Heart Diseases
Background: Direct oral anticoagulants (DOACs) have been widely applied in adults for thrombosis prophylaxis. However, the effect of DOACs in pediatric patients with congenital or acquired heart diseases who need anticoagulation therapy remains unclear. Methods: We systematically searched the databases of PubMed, Embase, and the Cochrane Library, as well as the ClinicalTrials.gov registry and the World Health Organization's International Clinical Trials Registry Platform until June 2024 to identify relevant randomized clinical trials (RCTs). If the number of included studies was less than 5, we performed a narrative review to assess the effect of DOACs in pediatric patients. Results: Four studies were included. In the UNIVERSE study, thrombotic events occurred in 2% of the rivaroxaban group and 9% of the aspirin group, with bleeding events in 36% and 41%, respectively. The ENNOBLE-ATE study showed no thromboembolic events in the edoxaban group and 1.7% in the SOC group (rate difference: −0.07%, 95% CI: −0.22 to 0.07%). Major bleeding rates were similar (rate difference: −0.03%, 95% CI: −0.18 to 0.12%). The SAXOPHONE trial showed no thromboembolic events in either group and similar major bleeding rates (−0.8%, 95% CI: −8.1 to 3.3%). In the DIVERSITY trial, 81% of dabigatran patients achieved the primary outcome versus 59.3% in the SOC group (Odds ratio: 0.342, 95% CI: 0.081–1.229). No major bleeding occurred in either group. Conclusion: Existing studies suggest that the use of DOACs hold promise as an effective and safe alternative for preventing and treating thromboembolism in pediatric patients with heart conditions.
- 1 January 2024
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Open AccessSystematic Review of Randomized Clinical Trials on Direct Oral Anticoagulants in Pediatric Heart Diseases
Background: Direct oral anticoagulants (DOACs) have been widely applied in adults for thrombosis prophylaxis. However, the effect of DOACs in pediatric patients with congenital or acquired heart diseases who need anticoagulation therapy remains unclear. Methods: We systematically searched the databases of PubMed, Embase, and the Cochrane Library, as well as the ClinicalTrials.gov registry and the World Health Organization's International Clinical Trials Registry Platform until June 2024 to identify relevant randomized clinical trials (RCTs). If the number of included studies was less than 5, we performed a narrative review to assess the effect of DOACs in pediatric patients. Results: Four studies were included. In the UNIVERSE study, thrombotic events occurred in 2% of the rivaroxaban group and 9% of the aspirin group, with bleeding events in 36% and 41%, respectively. The ENNOBLE-ATE study showed no thromboembolic events in the edoxaban group and 1.7% in the SOC group (rate difference: −0.07%, 95% CI: −0.22 to 0.07%). Major bleeding rates were similar (rate difference: −0.03%, 95% CI: −0.18 to 0.12%). The SAXOPHONE trial showed no thromboembolic events in either group and similar major bleeding rates (−0.8%, 95% CI: −8.1 to 3.3%). In the DIVERSITY trial, 81% of dabigatran patients achieved the primary outcome versus 59.3% in the SOC group (Odds ratio: 0.342, 95% CI: 0.081–1.229). No major bleeding occurred in either group. Conclusion: Existing studies suggest that the use of DOACs hold promise as an effective and safe alternative for preventing and treating thromboembolism in pediatric patients with heart conditions.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Direct Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: First Meta-Analysis of Prospective Studies
Direct oral anticoagulants (DOACs) are becoming increasingly popular clinically, but their safety and effectiveness profile in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is not well-established. Literature from the PubMed and EMBASE databases was systematically screened up to February 2024 to identify relevant studies on the use of DOACs in CTEPH patients. The bias risk of RCTs was assessed using the Cochrane Risk of Bias Tool 2.0. The quality of observational prospective cohorts was assessed using the Newcastle-Ottawa Scale tool. Data pooled from different studies were analyzed. Results from 4 studies were gathered, including 2 randomized controlled trials and 2 prospective cohorts, with a total of 2038 patients, of which 751 were on DOACs and 1287 were on vitamin K antagonists (VKAs). Similar rates of all-cause mortality (3.33% vs 3.33%, RD = −0.01%, 95% CI [−0.02%, 0.00%], P = .17), VTE recurrence (1.46% vs 2.12%, RD = −0.00%, 95% CI [−0.01%, 0.01%], P = .92) were observed. DOACs were associated with a nonsignificant reduction in bleeding events including major bleeding (2.22% vs 3.71%, RD = −0.01%, 95% CI [−0.04%, 0.01%], P = .30), any bleeding (5.33% vs 9.94%, RD = −0.03%, 95% CI [−0.07%, 0.01%], P = .10), and minor bleeding (4.17% vs 13.3%, RD = −0.06%, 95% CI [−0.23%, 0.10%], P = .45). Data pooled from existing perspective trials suggests the use of DOACs in CTEPH patients as an effective and safe alternative to VKAs.
- 1 January 2024
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Open AccessDirect Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: First Meta-Analysis of Prospective Studies
Direct oral anticoagulants (DOACs) are becoming increasingly popular clinically, but their safety and effectiveness profile in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is not well-established. Literature from the PubMed and EMBASE databases was systematically screened up to February 2024 to identify relevant studies on the use of DOACs in CTEPH patients. The bias risk of RCTs was assessed using the Cochrane Risk of Bias Tool 2.0. The quality of observational prospective cohorts was assessed using the Newcastle-Ottawa Scale tool. Data pooled from different studies were analyzed. Results from 4 studies were gathered, including 2 randomized controlled trials and 2 prospective cohorts, with a total of 2038 patients, of which 751 were on DOACs and 1287 were on vitamin K antagonists (VKAs). Similar rates of all-cause mortality (3.33% vs 3.33%, RD = −0.01%, 95% CI [−0.02%, 0.00%], P = .17), VTE recurrence (1.46% vs 2.12%, RD = −0.00%, 95% CI [−0.01%, 0.01%], P = .92) were observed. DOACs were associated with a nonsignificant reduction in bleeding events including major bleeding (2.22% vs 3.71%, RD = −0.01%, 95% CI [−0.04%, 0.01%], P = .30), any bleeding (5.33% vs 9.94%, RD = −0.03%, 95% CI [−0.07%, 0.01%], P = .10), and minor bleeding (4.17% vs 13.3%, RD = −0.06%, 95% CI [−0.23%, 0.10%], P = .45). Data pooled from existing perspective trials suggests the use of DOACs in CTEPH patients as an effective and safe alternative to VKAs.
- Open Access
- 16 November 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1070806
Effect of direct oral anticoagulants in patients with atrial fibrillation with mitral or aortic stenosis: A review
Background: Several studies have summarized the clinical performance of direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients with mitral stenosis or aortic stenosis. The significance of this review was to provide clinicians the latest update of the clinical application of DOACs in managing this specific population.Methods: Literatures from the PubMed database up to July 2022 were screened for inclusion. Studies on the effect of DOACs in patients suffering from AF with mitral or aortic stenosis were assessed for further selection.Results: Results from four studies were gathered: the RISE MS trial, the DAVID-MS study, and two observational studies. In the Korean observational study with a 27-month follow-up duration and a sample population consisted of patients with mitral stenosis and AF, the thromboembolic events happened at a rate of 2.22%/ year in the DOAC group and 4.19%/year in the warfarin group (adjusted hazard ratio: 0.28; 95% CI: 0.18–0.45). Intracranial hemorrhage occurred at rates of 0.49% and 0.93% in the DOAC and the warfarin groups, respectively (adjusted hazard ratio: 0.53; 95% CI: 0.22–1.26). In the Danish observational study, which had a sample pool with AF patients with aortic stenosis, reported that the adjusted hazard ratios for thromboembolism and major bleeding were 1.62 (95% CI, 1.08–2.45) and 0.73 (95% CI, 0.59–0.91) for DOACs compared with warfarin during 3 years of follow-up. In the RISE-MS trial involving AF patients with mitral stenosis, there were no differences in ischemic stroke, systemic embolic events, or major bleeding between the rivaroxaban vs. warfarin groups during a 1-year follow-up as well as equal rate of increased thrombogenicity in the left atrial appendage at 6 months. The rate of silent cerebral ischemia at 12 months was higher in the warfarin group (17.6%) than that in the rivaroxaban group (13.3%).Conclusions: Current published studies supported DOACs' effectiveness in preventing thromboembolism in patients of AF with mitral or aortic stenosis. Further clinical trials could confirm these findings.
- 16 November 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1070806
Open AccessEffect of direct oral anticoagulants in patients with atrial fibrillation with mitral or aortic stenosis: A review
Background: Several studies have summarized the clinical performance of direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients with mitral stenosis or aortic stenosis. The significance of this review was to provide clinicians the latest update of the clinical application of DOACs in managing this specific population.Methods: Literatures from the PubMed database up to July 2022 were screened for inclusion. Studies on the effect of DOACs in patients suffering from AF with mitral or aortic stenosis were assessed for further selection.Results: Results from four studies were gathered: the RISE MS trial, the DAVID-MS study, and two observational studies. In the Korean observational study with a 27-month follow-up duration and a sample population consisted of patients with mitral stenosis and AF, the thromboembolic events happened at a rate of 2.22%/ year in the DOAC group and 4.19%/year in the warfarin group (adjusted hazard ratio: 0.28; 95% CI: 0.18–0.45). Intracranial hemorrhage occurred at rates of 0.49% and 0.93% in the DOAC and the warfarin groups, respectively (adjusted hazard ratio: 0.53; 95% CI: 0.22–1.26). In the Danish observational study, which had a sample pool with AF patients with aortic stenosis, reported that the adjusted hazard ratios for thromboembolism and major bleeding were 1.62 (95% CI, 1.08–2.45) and 0.73 (95% CI, 0.59–0.91) for DOACs compared with warfarin during 3 years of follow-up. In the RISE-MS trial involving AF patients with mitral stenosis, there were no differences in ischemic stroke, systemic embolic events, or major bleeding between the rivaroxaban vs. warfarin groups during a 1-year follow-up as well as equal rate of increased thrombogenicity in the left atrial appendage at 6 months. The rate of silent cerebral ischemia at 12 months was higher in the warfarin group (17.6%) than that in the rivaroxaban group (13.3%).Conclusions: Current published studies supported DOACs' effectiveness in preventing thromboembolism in patients of AF with mitral or aortic stenosis. Further clinical trials could confirm these findings.